Theravance Biopharma (TBPH) Competitors $9.30 -0.19 (-2.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.30 0.00 (0.00%) As of 05/23/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH vs. SUPN, GLPG, ARQT, AGIO, SDGR, IRON, BHC, CNTA, INDV, and BHVNShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Supernus Pharmaceuticals (SUPN), Galapagos (GLPG), Arcutis Biotherapeutics (ARQT), Agios Pharmaceuticals (AGIO), Schrödinger (SDGR), Disc Medicine (IRON), Bausch Health Companies (BHC), Centessa Pharmaceuticals (CNTA), Indivior (INDV), and Biohaven (BHVN). These companies are all part of the "pharmaceutical preparations" industry. Theravance Biopharma vs. Supernus Pharmaceuticals Galapagos Arcutis Biotherapeutics Agios Pharmaceuticals Schrödinger Disc Medicine Bausch Health Companies Centessa Pharmaceuticals Indivior Biohaven Supernus Pharmaceuticals (NASDAQ:SUPN) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings. Do insiders and institutionals hold more shares of SUPN or TBPH? 99.1% of Theravance Biopharma shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer SUPN or TBPH? Supernus Pharmaceuticals presently has a consensus price target of $36.00, indicating a potential upside of 12.15%. Theravance Biopharma has a consensus price target of $11.33, indicating a potential upside of 21.86%. Given Theravance Biopharma's higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Supernus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has higher earnings & valuation, SUPN or TBPH? Supernus Pharmaceuticals has higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSupernus Pharmaceuticals$668.00M2.69$1.32M$1.1128.92Theravance Biopharma$65.27M7.12-$55.19M-$1.18-7.88 Is SUPN or TBPH more profitable? Supernus Pharmaceuticals has a net margin of 9.16% compared to Theravance Biopharma's net margin of -78.18%. Supernus Pharmaceuticals' return on equity of 7.79% beat Theravance Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Supernus Pharmaceuticals9.16% 7.79% 5.67% Theravance Biopharma -78.18%-24.79%-13.43% Does the MarketBeat Community prefer SUPN or TBPH? Supernus Pharmaceuticals received 140 more outperform votes than Theravance Biopharma when rated by MarketBeat users. Likewise, 73.18% of users gave Supernus Pharmaceuticals an outperform vote while only 62.94% of users gave Theravance Biopharma an outperform vote. CompanyUnderperformOutperformSupernus PharmaceuticalsOutperform Votes48373.18% Underperform Votes17726.82% Theravance BiopharmaOutperform Votes34362.94% Underperform Votes20237.06% Which has more volatility and risk, SUPN or TBPH? Supernus Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Does the media favor SUPN or TBPH? In the previous week, Supernus Pharmaceuticals had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for Supernus Pharmaceuticals and 3 mentions for Theravance Biopharma. Supernus Pharmaceuticals' average media sentiment score of 1.74 beat Theravance Biopharma's score of 0.99 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Theravance Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySupernus Pharmaceuticals beats Theravance Biopharma on 14 of the 17 factors compared between the two stocks. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$465.01M$6.47B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E Ratio-9.218.4026.7219.60Price / Sales7.12258.84395.56117.96Price / CashN/A65.8538.3234.62Price / Book2.176.416.764.50Net Income-$55.19M$143.73M$3.23B$248.40M7 Day Performance1.09%0.27%0.37%-1.03%1 Month Performance-2.52%0.09%7.04%7.94%1 Year Performance11.51%0.30%18.61%8.50% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma0.927 of 5 stars$9.30-2.0%$11.33+21.9%+8.8%$465.01M$65.27M-9.21359SUPNSupernus Pharmaceuticals2.6286 of 5 stars$33.05-1.1%$36.00+8.9%+15.6%$1.85B$668.00M30.89580Positive NewsGLPGGalapagos0.4672 of 5 stars$27.91+0.6%$25.33-9.2%+3.9%$1.84B$288.19M0.001,310Positive NewsARQTArcutis Biotherapeutics2.8099 of 5 stars$14.64+3.8%$18.80+28.4%+54.0%$1.75B$212.82M-8.18150News CoveragePositive NewsAnalyst ForecastInsider TradeAGIOAgios Pharmaceuticals3.9589 of 5 stars$29.84+2.3%$56.00+87.7%-8.8%$1.73B$37.04M2.63390Positive NewsAnalyst RevisionSDGRSchrödinger2.9291 of 5 stars$23.56-0.1%$32.80+39.2%-1.9%$1.72B$230.49M-10.07790News CoverageIRONDisc Medicine3.1053 of 5 stars$49.69+3.3%$98.80+98.8%+42.0%$1.72BN/A-12.4830Positive NewsInsider TradeBHCBausch Health Companies4.1219 of 5 stars$4.64-0.6%$7.42+59.8%-29.8%$1.68B$9.73B-38.6619,900Analyst RevisionCNTACentessa Pharmaceuticals3.5267 of 5 stars$12.26-2.0%$27.00+120.2%+54.1%$1.64B$6.85M-8.01200Positive NewsAnalyst UpgradeInsider TradeINDVIndivior3.2771 of 5 stars$11.68+3.0%$15.00+28.4%-32.7%$1.61B$1.17B-33.371,164News CoveragePositive NewsBHVNBiohaven3.3232 of 5 stars$15.75-1.7%$59.46+277.5%-57.1%$1.61BN/A-1.68239Gap Down Related Companies and Tools Related Companies SUPN Alternatives GLPG Alternatives ARQT Alternatives AGIO Alternatives SDGR Alternatives IRON Alternatives BHC Alternatives CNTA Alternatives INDV Alternatives BHVN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TBPH) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersMarket chaos is the new normalIt happened again. Wall Street swung like a wrecking ball after Trump paused tariffs on smartphones, lapto...Augusta Precious Metals | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TBPH Stock Free TBPH Stock Alerts